Volume 12, Number 8—August 2006
Bocavirus Infection in Hospitalized Children, South Korea
Highlight and copy the desired format.
|EID||Chung J, Han T, Kim C, Kim S. Bocavirus Infection in Hospitalized Children, South Korea. Emerg Infect Dis. 2006;12(8):1254-1256. https://dx.doi.org/10.3201/eid1208.060261|
|AMA||Chung J, Han T, Kim C, et al. Bocavirus Infection in Hospitalized Children, South Korea. Emerging Infectious Diseases. 2006;12(8):1254-1256. doi:10.3201/eid1208.060261.|
|APA||Chung, J., Han, T., Kim, C., & Kim, S. (2006). Bocavirus Infection in Hospitalized Children, South Korea. Emerging Infectious Diseases, 12(8), 1254-1256. https://dx.doi.org/10.3201/eid1208.060261.|
This study presents the first evidence of human bocavirus infection in South Korean children. The virus was detected in 27 (8.0%) of 336 tested specimens, including 17 (7.5%) of 225 virus-negative specimens, collected from children with acute lower respiratory tract infection.
Human respiratory syncytial virus (HRSV), human metapneumovirus (HMPV), parainfluenzavirus, coronavirus, and adenovirus are commonly detected viruses in children with acute lower respiratory tract infections (LRTI) (1–5). Recently, human bocavirus (HBoV) was identified as a cause of human respiratory tract infections in Sweden (6). Although HBoV was initially suspected to be an important human respiratory pathogen, the worldwide prevalence and clinical significance of the infection are still unclear. The purpose of this study was to investigate the prevalence of HBoV infection in children hospitalized with acute LRTI in South Korea.
A total of 336 specimens were evaluated for the presence of HBoV, including 225 virus-negative specimens (median age of patients = 14 months; range 1–69 months) and 111 virus-positive specimens (median age of patients = 15 months; range 1–83 months). The virus-positive specimens comprised 90 specimens with HRSV, 19 with HMPV, and 2 with adenovirus and were taken from hospitalized children with LRTI at Sanggyepaik Hospital from July 2004 through October 2005. LRTI included the diagnoses of bronchiolitis, bronchitis, pneumonia, and laryngotracheobronchitis. The 336 nasopharyngeal samples were consecutively collected at admission, after informed consent was obtained from the children's parents. Common respiratory viruses (HRSV, adenovirus, influenza A and B, parainfluenza) were detected by direct fluorescent-antibody assay kit (Dako Imagen, Cambridgeshire, UK), after admission. The remaining samples were stored at –70°C for further studies. Viral RNA was extracted from each sample by a QIAamp viral RNA mini kit (Qiagen, Hilden, Germany), and reverse transcription of 0.5 μg of each RNA sample was performed. Reverse transcription–PCR was performed to detect HMPV by using F-gene primers (7) and human coronavirus NL-63, by using a 1-a and a 1-b primer, as previously described (8).
DNA was extracted from the nasopharyngeal aspirates with a QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden, Germany). Two PCR assays were performed for each sample, 1 for the NP1 gene and the other for the NS1 gene, using different primer sets;188F (5´-GACCTCTGTAAGTACTATTAC-3´) and 542R (5´-CTCTGTGTTGACTGAATACA G-3´) for the NP1 gene; and HBoV01.2 (5´-TATGGCCAAGGCAATCGTCCAAG-3´) and HBoV02.2 (5´-GCCGCGTGAACATGAGAAACAGA-3´) for the NS1 gene, as previously described (6,9). Each cycle comprised predenaturation at 95°C for 3 min and 35 amplification cycles (denaturation at 95°C for 1 min, primer annealing [at 54°C for NP1 gene and 56°C NS1 gene] for 1 min, and extension at 72°C for 1 min). The amplified DNA fragments for the NP1 gene and NS1 gene were 354 bp and 291 bp, respectively. To validate the amplification process and exclude carryover contamination, positive and negative controls were run for each PCR, and positive samples were verified against an independent RNA extraction.
Amplicon was purified by using QIAquick (Qiagen GmbH) and sequenced in both directions with the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA). Sequencing products were resolved with an ABI 3730 XL autoanalyzer (Applied Biosystems). Nucleotides sequences were aligned with BioEdit v7.0 and presented in a topology tree, prepared in MEGA 3.1 (10).
This study presents the first evidence of HBoV infection in Korean children, which suggests that HBoV can infect humans worldwide (1,2). In this study, HBoV was detected in 27 (8.0%) of 336 tested specimens and in 17 (7.5%) of 225 virus-negative specimens collected from children with acute LRTI. A total of 15 (55.6%) of 27 HBoV-positive specimens were obtained from <1-year-old children, 8 (29.6%) of 27 1- to 2-year-old children, and 4 (14.8%) of 27 3- to 5-year-old children. Other viruses were also detected in 10 (37%) of 27 HBoV-positive specimens; 5 specimens also contained HRSV, 4 had HMPV, and 1 had adenovirus. Although HBoV was detected mostly in the winter in previous studies (6,9), we detected it throughout the study period.
The medical records of 17 patients with samples positive for only HBoV were retrospectively reviewed. The patients ranged in age from 1 to 37 months of age, and the male-to-female ratio was 2.8:1.The clinical manifestations of HBoV-positive patients were fever (76.4%), cough (76.4%), rhinorrhea (23.5%), gastrointestinal symptoms (11.7%), and rashes (5.8%). Direct sequencing of PCR products of the NS1 gene and NP1 genes showed that most strains had the same sequences (Figure 1 and Figure 2). The prevalence of HBoV in this study was higher than that in previous studies (3.14%–5.7%). This variation may be due to differences in the characteristics of the study populations and collection time of respiratory specimens (6,9,11). In our study, the positive rates of HBoV in the nasopharyngeal aspirates of patients with acute LRTI were relatively high. However, the clinical role of HBoV is still unclear because of a high frequency of co-infection (37%), a finding similar to those of previous studies (17.6%–55.6%) (6,9). In a future study, additional microbial testing for rhinovirus and coronaviruses, which are known to cause LRTIs, is needed to evaluate the precise rate of detection of >1 virus (12,13).
In conclusion, we confirmed HBoV infection in hospitalized children with acute LRTI in South Korea. Further prospective population-based studies are needed to confirm the role of HBoV in LRTI in children.
Dr Chung is a researcher at the Sanggyepaik Hospital, Inje University College of Medicine, South Korea. His research interests include viruses that cause respiratory tract infections in children and the molecular epidemiology of HMPV and HCoV NL-63.
- Selwyn BJ. The epidemiology of acute respiratory tract infection in young children; comparison of findings from several developing countries. Rev Infect Dis. 1990;12:S870–88.
- Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917–28.
- van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7:719–24.
- Boivin G, Abed Y, Pelletier G, Ruel L, Moisan D, Cote S, Virological features and clinical manifestations associated with the human metapneumovirus, a new paramyxovirus responsible for acute respiratory tract infections in all age groups. J Infect Dis. 2002;186:1330–4.
- van der Hoek L, Sure K, Ihorst G, Stang A, Pyrc K, Jebbink MF, Croup is associated with the novel coronavirus NL63. PLoS Med. 2005;2:e240.
- Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A. 2005;102:12891–6.
- van den Hoogen BG, Herfst S, Sprong L, Cane PA, Forleo-Neto E, de Swart RL, Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis. 2004;10:658–69.
- Arden KE, Nissen MD, Sloots TP, Mackay IM. New human coronavirus, HCoV-NL63, associated with severe lower respiratory tract disease in Australia. J Med Virol. 2005;75:455–62.
- Sloots TP, McErlean P, Speicher DJ, Arden KE, Nissen MD, MacKay IM. Evidence of human coronavirus HKU-1 and human bocavirus in Australian children. J Clin Virol. 2006;35:99–102.
- Kumar S, Tamura K, Jakobsen IB, Nei M. MEGA2; molecular evolutionary genetics analysis software. Bioinformatics. 2001;17:1244–5.
- Ma X, Endo R, Ishiguro N, Ebihara T, Ishiko H, Ariga T, Detection of human bocavirus in Japanese children with lower respiratory tract infections. J Clin Microbiol. 2006;44:1132–4.
- Hayden FG. Rhinovirus and the lower respiratory tract. Rev Med Virol. 2004;14:17–31.
- van Elden LJ, van Loon AM, van Alphen F, Hendriksen KA, Hoepelman AI, van Kraaij MG, Frequent detection of human coronaviruses in clinical specimens from patients with respiratory tract infection by use of a novel real-time reverse-transcriptase polymerase chain reaction. J Infect Dis. 2004;189:652–7.
- Figure 1. Phylogenetic analysis of Korea (KR-MN), Sweden (st), USA (CRD2), and Queensland (Q) NS1 gene sequences from human bocavirus strains presented on a topology tree prepared in MEGA3.1. Nucleotide alignment...
- Figure 2. Phylogenetic analysis of Korean (KR-MN), Swedish (st), Jordanian (Jord), French (MP), USA (CRD2), and Japanese (JPBS) NP1 gene sequences from human bocavirus strains presented on a topology tree prepared...
Please use the form below to submit correspondence to the authors or contact them at the following address:
Ju-Young Chung, Sanggye Paik Hospital, Inje University College of Medicine – Pediatrics; 761-1 Sanggye 7-Dong, Nowon-Gu, Seoul, South Korea 139-707
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: December 09, 2011
- Page last updated: December 09, 2011
- Page last reviewed: December 09, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)